179 related articles for article (PubMed ID: 12435109)
1. Overcoming multidrug resistance in taxane chemotherapy.
Geney R; Ungureanu lM; Li D; Ojima I
Clin Chem Lab Med; 2002 Sep; 40(9):918-25. PubMed ID: 12435109
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the new generation taxane anticancer agents.
Geney R; Chen J; Ojima I
Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308
[TBL] [Abstract][Full Text] [Related]
3. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
4. Development of taxane resistance in a panel of human lung cancer cell lines.
Breen L; Murphy L; Keenan J; Clynes M
Toxicol In Vitro; 2008 Aug; 22(5):1234-41. PubMed ID: 18514476
[TBL] [Abstract][Full Text] [Related]
5. Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.
Ehrlichova M; Vaclavikova R; Ojima I; Pepe A; Kuznetsova LV; Chen J; Truksa J; Kovar J; Gut I
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jul; 372(1):95-105. PubMed ID: 16059735
[TBL] [Abstract][Full Text] [Related]
6. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z
J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562
[TBL] [Abstract][Full Text] [Related]
7. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
8. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray S; Briasoulis E; Linardou H; Bafaloukos D; Papadimitriou C
Cancer Treat Rev; 2012 Nov; 38(7):890-903. PubMed ID: 22465195
[TBL] [Abstract][Full Text] [Related]
9. Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line.
Murphy L; Henry M; Meleady P; Clynes M; Keenan J
Biochim Biophys Acta; 2008 Sep; 1784(9):1184-91. PubMed ID: 18503785
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
11. The use of ultrasound to increase the uptake and cytotoxicity of dual taxane and P-glycoprotein inhibitor loaded, solid core nanoparticles in drug resistant cells.
Jackson J; Leung D; Burt H
Ultrasonics; 2020 Feb; 101():106033. PubMed ID: 31561207
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and SAR study of 3rd-generation taxoids bearing 3-CH
Wang C; Wang X; Sun Y; Taouil AK; Yan S; Botchkina GI; Ojima I
Bioorg Chem; 2020 Jan; 95():103523. PubMed ID: 31911305
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in design, synthesis and bioactivity of paclitaxel-mimics.
Wen G; Qu XX; Wang D; Chen XX; Tian XC; Gao F; Zhou XL
Fitoterapia; 2016 Apr; 110():26-37. PubMed ID: 26906104
[TBL] [Abstract][Full Text] [Related]
14. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
15. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
16. Substituents at the C3' and C3'N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel.
Jelínek M; Balušíková K; Daniel P; Němcová-Fürstová V; Kirubakaran P; Jaček M; Wei L; Wang X; Vondrášek J; Ojima I; Kovář J
Toxicol Appl Pharmacol; 2018 May; 347():79-91. PubMed ID: 29625142
[TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors reverse taxane resistance.
Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Díaz F; Giannakakou P
Cancer Res; 2006 Sep; 66(17):8838-46. PubMed ID: 16951201
[TBL] [Abstract][Full Text] [Related]
19. Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action.
Zhang Y; Li H; Wang H; Su F; Qu R; Yin D; Dai J; Li Y; Chen X
Cancer Chemother Pharmacol; 2010 Oct; 66(5):851-9. PubMed ID: 20052473
[TBL] [Abstract][Full Text] [Related]
20. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
Huisman MT; Chhatta AA; van Tellingen O; Beijnen JH; Schinkel AH
Int J Cancer; 2005 Sep; 116(5):824-9. PubMed ID: 15849751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
